**Novel Systemic Treatments in High Grade Ovarian Cancer Cancer**

**Novel Systemic Treatments in High Grade Ovarian** 

DOI: 10.5772/intechopen.71583

Amit Samani, Charleen Chan and Jonathan Krell

Amit Samani, Charleen Chan and Jonathan Krell Additional information is available at the end of the chapter

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/intechopen.71583

#### **Abstract**

Most patients with ovarian cancer present at an advanced stage and are never cured. To improve outcomes a variety of novel systemic strategies are being developed. Traditional cytotoxic chemotherapy is being optimised, anti-angiogenic strategies are already in the clinic and several PARP inhibitors have gained regulatory approval. In addition, immunotherapy is showing promise and novel targeted strategies including against folate receptor alpha are also generating excitement. As our therapeutic choice increases, a challenge will be how to best utilize the options available. Here we discuss recently established and other emerging therapies with a focus on key concepts rather than detailed synopses of trial designs and outcomes.

**Keywords:** ovarian cancer, PARP inhibitors, immunotherapy, antiangiogenic therapy
